Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Active, not recruiting · NCT04301843 · Registry updated 2026-09-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-09-03 | NCT04301843 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beat NB Cancer Foundation | 3 |
| Giselle Sholler | 7 |
| K C Pharmaceuticals Inc. | 2 |
| Team Parker for Life | 3 |
| USWM, LLC | 1 |
29 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.